daclatasvir (Daklinza)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

Adverse effects

* in combination with sofosbuvir

Drug interactions

Mechanism of action

  • NS5A replication complex inhibitor

More general terms

References

  1. 1.0 1.1 Lok AS et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012 Jan 19; 366:216. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22256805
    Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012 Jan 19; 366:273. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22256811
  2. 2.0 2.1 2.2 Brooks M FDA Clears Two New Oral Drugs for Hepatitis C. Medscape Oncology. July 24, 2015 http://www.medscape.com/viewarticle/848650
  3. 3.0 3.1 FDA Drug Safety Communication: Oct 4, 2016 FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
  4. 4.0 4.1 4.2 Mucke MM, Backus LI, Mucke VT et al Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology. Jan 19, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29371017 <Internet> http://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30002-5/fulltext

Database